Background. To compare the analgesic efficacy of remifentanil with meperidine and fentanyl in a patient-controlled setting ( patient-controlled analgesia, PCA).
Epidural analgesia is considered to be the most effective method of pain relief during labour. However, there are situations in which epidural analgesia is contra-indicated, for example, patients with coagulation or platelet disorders or refusal of epidural analgesia.
At this moment, the most commonly used alternative for epidural analgesia is (i.m.) meperidine, although its efficacy is widely challenged. 1 -3 For these reasons, there is great need for new analgesic methods during labour.
Remifentanil, the hydrochloride salt of 3-[4-methoxycarbonyl-4-[(1-oxopropyl)phenylamino]-1-piperidine]propanoic acid methyl ester, is a synthetic opioid (anilidopiperidine) with direct agonist action specifically on m-opioid receptors. Its rapid hydrolysis by non-specific blood and tissue esterases to an inactive metabolite results in a very short duration of action. The pharmacodynamic profile of remifentanil is characterized by a rapid onset of action and short latency to its peak effect. The contextsensitive half-life is 3 -4 min and the elimination half-time ranges from 10 to 20 min. Most of an i.v. dose is excreted in the urine as the carboxylic acid metabolite. The metabolism of remifentanil is independent of renal and hepatic function and there is no accumulation during repeat bolus injection. 4 5 Placental transfer of remifentanil does occur but in the neonate it appears to be rapidly metabolized, redistributed, or both. 6 The rapid onset and offset of remifentanil are suitable characteristics for patient-controlled analgesia (PCA).
Another possible opioid during labour is fentanyl. Fentanyl PCA during labour has been studied before. 7 -9 One study compared i.v. fentanyl with i.v. meperidine during labour and found that fentanyl was preferable to meperidine because there appeared to be less maternal side-effects and fewer requirements for naloxone. 10 There are no studies comparing these three opioids in a patient-controlled method. A recent Belgian survey investigating the use of analgesic alternatives to epidural analgesia showed that remifentanil was the first choice when using patient-controlled i.v. analgesia, but other opioids including sufentanil and fentanyl were also used.
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The main objective of this prospective, randomized, double-blind study was to compare the analgesic efficacy of remifentanil with meperidine and fentanyl in a patientcontrolled i.v. analgesia setting.
Methods
The study protocol was approved by the local Research Ethics Committee. After obtaining written informed consent in the antenatal clinic or before the onset of active labour, 180 women requesting analgesia other than epidural analgesia were studied. All women were healthy (ASA physical status I or II) term parturients in an active stage of labour, with singleton cephalic presentation, without prior administration of opioid analgesics. Exclusion criteria included obesity (BMI40 kg m
22
), opioid allergy, substance abuse history, and high-risk patients ( pre-eclampsia, severe asthma, insulin-dependent diabetes mellitus, hepatic insufficiency, or renal failure).
Randomization was established by using a computergenerated random sequence in numbered envelopes. Women were randomly allocated to one of three groups, each group containing 60 parturients. Study medication was prepared and blinded by the hospital pharmacy. There were three pre-programmed PCA devices (Braun Perfusor fm PCA, Braun Melsungen, Germany) available, each set to deliver the corresponding dose and with the appropriate lock-out interval. Observants and medical personnel attending to the parturient were unaware of the drug assignment.
Women allocated to the remifentanil group (Group R) received a 40 mg loading dose and remifentanil 40 mg per bolus with a lockout of 2 min and a maximum dose limit of 1200 mg h
21
. The specific dose regimen was based on previous studies. 12 13 Women randomized to receive meperidine (Group P) received a 49.5 mg loading dose and 5 mg boluses with a lockout of 10 min and a maximum overall dose limit of 200 mg. Women in the fentanyl group (Group F) received a 50 mg loading dose and boluses of 20 mg with a lockout of 5 min and a maximum dose limit of 240 mg h
. 9 All women received similar instructions on how to use the PCA device: all parturients were instructed to press the bolus button whenever they needed pain relief. They were told to press the button as often as they felt necessary and it was explained that each pump was programmed to monitor the total dose administered and that safety limits were set to avoid an overdose. It was explained that this implied the possibility that not every request would be rewarded. All women were free to change to epidural analgesia at any time. The PCA device was discontinued at full cervical dilatation.
With the exception of baseline data, all observations and measurements were made by blinded observers. Observants entered the delivery room only after the PCA device had been connected and the loading dose had been administered. This way the observants were unable to notice time differences in the administration of the loading dose, which might have jeopardized blinding. Observants had no knowledge of the differences in programming of the PCA devices.
Non-invasive measurements were made before starting the study protocol and at regular intervals thereafter, including maternal arterial pressure, heart rate, ventilatory frequency, and pulse oximetry. Measurements were recorded every 30 min. Hypotension (systolic arterial pressure ,90 mm Hg or .25% below baseline) was treated with i.v. fluids and ephedrine 5 mg i.v. When oxygen saturation decreased below 95%, oxygen 6 litre min 21 was administered by facemask. Pain scores were assessed using a visual analogue scale (VAS) ranging from 0 to 10 cm. Women were asked to mark the level of pain experienced during contractions every hour, starting with a baseline VAS score before institution of analgesia. In addition, an observer sedation score (1, awake; 2, sleepy; 3, eyes closed, but rousable by vocal stimulus; 4, eyes closed, but rousable by physical stimulus; and 5, unrousable) was recorded hourly. Two hours after delivery, the parturients were asked to score their overall satisfaction on a 10-point scale. 1 -10 Fetal heart rate and uterine activity were measured continuously by external monitoring. When data were difficult to interpret or in the case of complications (such as meconium-stained amniotic fluid, failure to progress in labour), invasive monitoring by means of scalp electrode and intra-uterine pressure recording was instituted. Fetal heart rate patterns were scored as reactive or non-reactive at regular intervals by an obstetrician who was blinded to the treatment groups.
The incidence of side-effects such as nausea/vomiting and itching was recorded.
At delivery, neonatal outcome including Apgar scores at 1 and 5 min, cord blood gas analysis, and the Neurologic and Adaptive Capacity Score (NACS) was recorded.
14 The NACS was performed at 15 min and 2 h after delivery. The need for oxygen and neonatal requirement for naloxone were also recorded. Both maternal and cord blood samples were obtained to measure opioid concentrations.
If labour failed to progress (first or second stage), oxytocin was given, according to the hospital protocol.
A ventilatory frequency ,8 min
, Sp O 2 ,90% for .15 s and not being resolved with oxygen, and a maternal heart rate ,50 beats min 21 were considered serious adverse events, in which case the patient was withdrawn from the study.
For safety reasons, the observer collecting the data was present in the delivery suite at all times until discontinuation of the study medication.
For sample size calculation, we hypothesized that average pain scores in the remifentanil or fentanyl group would differ at least 10% from the meperidine group. Assuming an SD of 15 mm based on the previous studies, we calculated a sample size of 60 parturients per group for a power of 0.95 and a two-sided a level of 0.05 to detect this difference. Data analysis was per-protocol. Numerical variables between the groups were compared using the two-tailed Kruskal-Wallis test and post hoc Dunn's multiple comparison test; categorical data were analysed using the x 2 test. Intragroup comparisons were made using the two-tailed Wilcoxon matched-pairs signed-ranks test. A value of P,0.05 was considered statistically significant.
Results
One hundred and eighty parturients were enrolled, of which 159 parturients completed the study: 52 received remifentanil, 53 received meperidine, and 54 received fentanyl. Twenty-one parturients were excluded because they delivered within 1 h after randomization ( Table 1) .
The characteristics of the parturients did not differ statistically. Details of the three groups are listed in Table 2 . Duration of labour, oxytocin use, and the incidence of nausea/vomiting did not differ between the three groups. Itching occurred more frequently in Group R (16%) compared with Group P (6%) and Group F (2%). Significantly more parturients crossed over to epidural analgesia in Group P (34% vs 13% in Group R and 15% in Group F). In Group F, significantly more parturients delivered spontaneously (85% vs 62% in Group R and 69% in Group P). Differences in instrumental delivery and Caesarean section rate were not statistically significant.
There was no difference in baseline pain scores between the three groups. In all groups, pain scores decreased significantly from baseline 1 h after the start of treatment.
After the first hour, pain scores started to return towards baseline in all groups. At 2 h, pain scores in Group P were not significantly different from baseline. Three hours after the initiation of treatment, pain scores were not significantly different from baseline in any of the groups.
Intergroup comparison showed that the decrease in pain scores after 1 h was significantly greater in Group R [23.2 (SD 2.9) cm] compared with Group F [21.4 (2.4) cm] and Table 3 and Figure 1 . Sedation scores increased significantly compared with baseline levels during treatment in all groups. The increase in sedation was greatest in Group R; after 1 and 2 h, the increase in sedation in Group R was significantly greater compared with Groups P and F. After 3 h, the increase in sedation in Group R was significantly greater compared with Group F. The differences in sedation scores between Groups P and F were not statistically significant at any time interval. Data on sedation scores are summarized in Table 4 .
There were no differences between the groups in maternal arterial pressure, heart rate, and ventilatory frequency. After 1 h of administration, the decrease in oxygen saturation was greater in Group R [21.13 (2.6)] compared with Group P [20.04 (1.9)]. However, between Groups R and F [20.72 (1.9)], this difference was not significant (Table 5 ). More parturients in Group R (74%) and Group F (56%) experienced one or more periods of desaturation (oxygen saturation ,95%) compared with Group P (33%). Six parturients in Group R (12%) were administered supplemental oxygen vs four in Group P (8%) and one in Group F (2%). Data on oxygen saturation are summarized in Tables 5 and 6. Overall satisfaction, measured after delivery, was greatest in Group R [8.1 (1.1) vs 7.0 (1.5) for Group P and 7.3 (1.2) for group F], the difference being significant compared with Group P (Table 7) .
There were no differences in fetal heart rate traces between the three groups. In terms of Apgar score, NACS, and fetal cord blood, neonatal outcome was similar in all groups (Table 8) .
Discussion
Overall, the decrease in pain scores varied from mild to moderate, average pain scores remaining above 4.5 cm in all groups. Remifentanil PCA performed significantly better than meperidine and fentanyl PCA, but only during the first hour of treatment. Although the decrease in pain scores was greatest in Group R at all time intervals, the difference was only significant at 1 h. In all the three groups, pain scores started to increase towards baseline after 1 h of treatment. Meperidine PCA performed worst, with pain scores not differing significantly from baseline 2 h after the initiation of treatment, and significantly more parturients crossing over to epidural analgesia. In all three groups, pain scores no longer differed significantly from baseline 3 h after treatment was started.
Overall satisfaction scores were higher for remifentanil PCA, but remifentanil PCA produced more sedation compared with meperidine and fentanyl PCA.
There have been multiple clinical studies on the use of remifentanil in the parturient. 12 13 15 -25 Some studies comparing remifentanil PCA with meperidine showed better results for remifentanil. 13 19 20 22 However, these studies contain relatively small groups of patients; in some studies, the observation period was limited, and in a number of studies, labouring women were allowed to use nitrous oxide concomitantly, which may have affected the results.
Our results are in agreement with Volikas and Male 19 and Evron and colleagues, 22 who reported significantly lower pain scores with remifentanil compared with Table 3 Intra-and intergroup comparison pain. Data are means (SD). NS, not significant; R vs P, remifentanil vs meperidine; R vs F, remifentanil vs fentanyl; P vs F, meperidine vs fentanyl; DELTA, change in VAS score relative to the VAS score at inclusion meperidine. Most previous studies only evaluated the first 2 h of administration of remifentanil. In our study, we assessed pain scores up to 3 h. This is an important difference with other studies, as we noticed a return towards baseline VAS scores of all three opioids over time, with pain scores returning to pre-treatment levels in all groups after 3 h of treatment. It should be noted that this observation does not imply a lack of effect as pain scores are known to increase during labour. 26 The use of a background infusion with i.v. PCA with remifentanil is disputable. The rapid offset of remifentanil does not promote reaching a steady-state plasma concentration when using only intermittent boluses, and from this pharmacokinetic perspective, adding a background infusion would seem rational. However, one study comparing different bolus doses with or without background infusion found bolus doses of remifentanil 0.25 -0.5 mg kg 21 without background infusion most suitable for labour analgesia. 12 In addition, low oxygen saturations with remifentanil were reported in previous studies when using a background infusion. We therefore chose to use only intermittent boluses. However, our results show that despite the absence of a background infusion, the use of intermittent remifentanil was still associated with episodes of maternal desaturation (oxygen saturation ,95%).
We limited the total dose of meperidine to 200 mg, as this is considered to be the maximum dose used in Dutch obstetric units. Although it may be argued that this dose Table 4 Intra-and intergroup comparison observer sedation. Data are means (SD). NS, not significant; R vs P, remifentanil vs meperidine; R vs F, remifentanil vs fentanyl; P vs F, meperidine vs fentanyl; DELTA, change in observer sedation score relative to the score at inclusion limit is conservative, none of the parturients in the meperidine group reached the maximum dose limit in the 5 h time frame that resulted from our dosing regime. Five parturients reached the maximum dose limit, all of them beyond the 5 h time frame (385 -500 min). We therefore do not believe that our dosing regime adversely affected outcome in the meperidine group. The most concerning adverse effect of i.v. opioids on the labour ward is respiratory depression. During administration of remifentanil, the decrease in oxygen saturation was significantly greater when compared with meperidine; during the first 2 h of treatment, the use of remifentanil was associated with significantly more sedation when compared with fentanyl and meperidine. Although these side-effects will be quickly reversible considering the short half-life of remifentanil, a high level of sedation and periods of desaturation are undesirable side-effects during labour.
There was no difference in neonatal outcome between the groups. This is an important finding, as it would be expected that over time remifentanil would have less effect on the neonate compared with longer-acting agents such as meperidine or fentanyl.
Interestingly, we found that significantly more parturients receiving fentanyl PCA delivered spontaneously when compared with the women receiving either meperidine or remifentanil PCA; the explanation for this finding is unclear and further study is required to establish whether this significance is spurious or valid.
In conclusion, under the conditions of our study, remifentanil PCA was more effective than meperidine and fentanyl PCA in providing pain relief during labour, but it was associated with significantly more sedation and itching compared with both other opioids and more periods of maternal oxygen saturation decreasing below 95% compared with meperidine. Its effectiveness was time-limited (2 h); therefore, we would recommend the use of remifentanil only in the last phase of cervical dilation. Because remifentanil is a potent respiratory depressant, continuous monitoring is required. Further studies are needed to determine the safety of remifentanil especially with relation to its respiratory effects.
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